CD274 and breast cancer: However, at the biomarker-defined analysis, patients with tumor BRCA mutations (n = 15) or with PD-L1-positive disease (n = 28) had a numerically higher ORR compared to those with BRCA wild-type (ORR = 47% vs. 11%) or PD-L1-negative BC (ORR = 32% vs. 8%) [113].